

Doxorubicin-induced reactive oxygen species generation and intracellular Ca^{2+} increase are reciprocally modulated in rat cardiomyocytes

Seon-Young Kim^{1,2,*}, Sang-Jin Kim^{1,2,*},
Byoung-Joo Kim¹, So-Young Rah¹,
Sung Mo Chung¹, Mie-Jae Im¹ and
Uh-Hyun Kim^{1,2,3}

¹Department of Biochemistry and

²Institute of Cardiovascular Research

Chonbuk National University Medical School

Jeonju, 561-182, Korea

³Corresponding author: Tel, 82-63-270-3083;

Fax, 82-63-274-9833; E-mail, uhkim@chonbuk.ac.kr

*These authors contributed equally to this work.

Accepted 20 September 2006

Abbreviations: $[\text{Ca}^{2+}]_i$, intracellular Ca^{2+} concentration; DOX, doxorubicin; ROS, reactive oxygen species; RyR, ryanodine receptor; SR, sarcoplasmic reticulum

Abstract

Doxorubicin (DOX) is one of the most potent anticancer drugs and induces acute cardiac arrhythmias and chronic cumulative cardiomyopathy. Though DOX-induced cardiotoxicity is known to be caused mainly by ROS generation, a disturbance of Ca^{2+} homeostasis is also implicated one of the cardiotoxic mechanisms. In this study, a molecular basis of DOX-induced modulation of intracellular Ca^{2+} concentration ($[\text{Ca}^{2+}]_i$) was investigated. Treatment of adult rat cardiomyocytes with DOX increased $[\text{Ca}^{2+}]_i$ irrespectively of extracellular Ca^{2+} , indicating DOX-mediated Ca^{2+} release from intracellular Ca^{2+} stores. The DOX-induced Ca^{2+} increase was slowly processed and sustained. The Ca^{2+} increase was inhibited by pretreatment with a sarcoplasmic reticulum (SR) Ca^{2+} channel blocker, ryanodine or dantrolene, and an antioxidant, α -lipoic acid or α -tocopherol. DOX-induced ROS generation was observed immediately after DOX treatment and increased in a time-dependent manner. The ROS production was significantly reduced by the pretreatment of the SR Ca^{2+} channel blockers and the antioxidants. Moreover, DOX-mediated activation of caspase-3 was significantly inhibited by the Ca^{2+}

channel blockers and α -lipoic acid but not α -tocopherol. In addition, cotreatment of ryanodine with α -lipoic acid resulted in further inhibition of the caspase-3 activity. These results demonstrate that DOX-mediated ROS opens ryanodine receptor, resulting in an increase in $[\text{Ca}^{2+}]_i$ and that the increased $[\text{Ca}^{2+}]_i$ induces ROS production. These observations also suggest that DOX/ROS-induced increase of $[\text{Ca}^{2+}]_i$ plays a critical role in damage of cardiomyocytes.

Keywords: apoptosis; calcium signaling; doxorubicin; myocytes, cardiac; reactive oxygen species

Introduction

An anthracyclin derivative, doxorubicin (DOX) is a highly effective anticancer drug that is widely used in treatment of a broad spectrum of cancers (Minotti *et al.*, 2004). The clinical efficacy of this drug is compromised due to manifestation of atrial and ventricular arrhythmia and development of cumulative dose-dependent cardiomyopathy and heart failure (Singal and Iliskovic, 1998; Minotti *et al.*, 2004). One of the proposed mechanisms of DOX-induced cardiac dysfunction is an oxidation of cellular components via formation of reactive oxygen species (ROS) (Minotti *et al.*, 2004). Several mechanisms of DOX-mediated ROS generation have been proposed. The quinone moiety of DOX is prone to the generation of oxygen radicals through enzymatic mechanism utilizing mitochondrial respiratory chain and nonenzymatic pathway, which incorporates iron (Gutierrez, 2000; Shadle *et al.*, 2000). In mitochondrial respiratory chain coupled to increased ROS production, several enzymes, including cytochrome p450, NAD(P)H dehydrogenase, and endothelial nitric oxide synthase, have been implicated to catalyze the reductive metabolism of DOX (Doroshov and Davies, 1986; Childs *et al.*, 2002).

Although less attention than ROS has been received, a number of studies has suggested that DOX-mediated alteration of Ca^{2+} homeostasis is one of the possible mechanisms of cardiotoxicity. Very recent studies have demonstrated that DOX-mediated ROS generation and apoptosis are inhibited by reducing intracellular Ca^{2+} level using a Ca^{2+}

chelator (Kalivendi *et al.*, 2001; 2005). Direct effects of the drug on various Ca^{2+} channels have also been observed. DOX increases the open probability of sarcoplasmic reticulum (SR) calcium release channels (Zorzato *et al.*, 1985; Kim *et al.*, 1989), inhibits Na^+ - Ca^{2+} exchanger (Caroni *et al.*, 1981) or activates L-type cardiac calcium channel (Keung *et al.*, 1991). All of these DOX effects on Ca^{2+} channels can lead to Ca^{2+} overload of cardiac cells that may render mitochondrial calcium overloading, resulting in alteration of energy metabolism and generation of reactive oxygen species (ROS). In addition, an increase in intracellular Ca^{2+} level promotes ROS generation (Przygodzki *et al.*, 2005), and also modulates mitochondrial permeability transition by opening permeability transition pores, therewith releasing cytochrome c, a critical step for apoptosis (Petrosillo *et al.*, 2004; Waring, 2005).

In this study, we have investigated the molecular basis of DOX-mediated regulation of $[\text{Ca}^{2+}]_i$ utilizing freshly isolated adult rat cardiomyocytes. The results have shown that DOX-mediated ROS formation increases $[\text{Ca}^{2+}]_i$ by releasing Ca^{2+} from SR via ryanodine receptor (RyR) and that ROS-induced rise of $[\text{Ca}^{2+}]_i$ generates further ROS.

Materials and Methods

Isolation of adult rat cardiomyocytes

Cardiomyocytes were isolated from Sprague-Dawley rats, weighing 210-240 g, by the method with a slight modification (Xie *et al.*, 2003). Rat hearts were rapidly excised, cannulated, and subjected to retrograde perfusion on a Langendorff apparatus at 37°C with Ca^{2+} -free Krebs-Hanseleit (KH) buffer (10 mM HEPES, 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO_4 , 1.2 mM KH_2PO_4 , 25 mM NaHCO_3 , 10 mM pyruvate, 11 mM glucose, and 1 mM CaCl_2 , pH 7.3) for 5 min and then with KH buffer containing 5 mM taurine, 0.075% collagenase Type II and 0.08 $\mu\text{g}/\text{l}$ protease type XIV for 7-15 min and washed with KH buffer containing 0.2 mM Ca^{2+} . The left ventricle was removed, chopped into small pieces and further digested in a glass conical flask at 37°C for 10 min with shaking. The undigested tissues were removed through a 200 μm -mesh nylon sheet. The Ca^{2+} concentration in the cell preparation was gradually increased up to 1 mM. Isolated myocytes were pelleted by centrifugation at $60 \times g$ for 2 min at room temperature and resuspended in a stabilizing buffer (pH 7.4) containing 20 mM HEPES, 137 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO_4 , 15 mM glucose, and 10 mM 2,3-butanedione monoxime (BDM). The cell preparation was kept in the stabilizing buffer containing 1% bovine serum albumin (BSA) at room temperature for 1.5 h and

then washed three times with MEM medium at 37°C. The cells were attached on laminine (10 $\mu\text{g}/\text{ml}$)-coated confocal plates and incubated at 37°C in 5% $\text{CO}_2/95\%$ air humidified incubator before Ca^{2+} measurement.

Preparation of rat cardiac sarcoplasmic reticulum (SR)

Rat cardiac SR vesicles were prepared using a slight modification of a method reported previously (Chamberlain and Fleisher, 1988). Rats of either sex (250-300 g) were euthanized and the hearts were immediately removed, immersed in ice-cold saline, and trimmed off fat and connective tissues. The hearts were transferred in 5 volumes of imidazole buffer (0.29 M sucrose, 0.5 mM DTT, 10 mM imidazole-HCl, pH 6.9), homogenized (three times, a 15-s interval, high setting), and centrifuged at $3,800 \times g$ for 15 min at 4°C. The supernatant was centrifuged at $27,900 \times g$ for 15 min. The supernatant from second centrifugation was centrifuged at $119,200 \times g$ for 2 h at 4°C. The pellets were collected and suspended in a buffer (0.29 M sucrose, 0.65 M KCl, 0.5 mM DTT, 3 mM NaN_3 , 0.5 mM PMSF, 10 mM imidazole-HCl, pH 6.7). After 30 min on ice, the suspension was centrifuged to remove large aggregates at $4,400 \times g$ for 10 min. The supernatants were then centrifuged at $120,000 \times g$ for 100 min at 4°C. After removal of the supernatants by aspiration, the pellets were resuspended in a minimal volume of the same buffer and stored at -80°C until use. Protein concentrations were determined using the protein assay kit (Bio-Rad Laboratories, Hercules, CA), and known concentrations of BSA were used as the standard.

$[\text{}^3\text{H}]$ ryanodine binding assay

Binding of $[\text{}^3\text{H}]$ ryanodine (Du Pont-New England Nuclear, Boston, MA) to cardiac SR was performed as described previously (Takeda *et al.*, 2003). Briefly, cardiac SR (70 μg) was incubated with 5 nM $[\text{}^3\text{H}]$ ryanodine (specific activity, 50 Ci/mmol) at 37°C for 1 h in a binding buffer (25 mM imidazole, pH 7.4, 1 M KCl, 1 mM EDTA, and 1 mM CaCl_2). The reaction mixtures were quenched in an ice-water bath for 20 min and then fast filtered on GF-C (Whatman, International Ltd, Maidstone, UK) filters using a Millipore fast filter apparatus (Millipore Corp. Bedford, MA). The GF-C filters were pretreated with 1% polyethylene glycol for 1 h. After five time washes with a buffer (25 mM imidazole, pH 7.4, and 1 M KCl), the radioactivity remaining on the filters was determined by a liquid scintillation counter. Nonspecific binding was determined in the presence of 5 μM unlabeled ryanodine.

Determination of Ca^{2+} uptake and release by SR

Measurement of Ca^{2+} release from SR vesicles was performed spectrophotometrically using a dye antipyrylazo III as a Ca^{2+} sensor according to the method described previously (Olson *et al.*, 2000). Cardiac SR preparation (88 mg/tube) was preloaded with Ca^{2+} by adding 0.98 ml of a reaction solution (0.15 mM antipyrylazo III, 20 mM HEPES, 5 mM KCl, 5 mM $MgCl_2$, 5 mM sodium oxalate, 5 mM ATP, 5 mM NaN_3 , pH 7.0) at 37°C. Subsequently, Ca^{2+} was loaded to SR by addition of 6 times of $CaCl_2$ (40 nM each). Calcium loading and release induced by DOX (3 μ M) were monitored by the difference in absorbance between 710 nm and 790 nm using a Beckman 530 UV/VIS spectrophotometer. Various Ca^{2+} channel blockers were preincubated for 30 min prior to treatment with DOX.

Determination of $[Ca^{2+}]_i$

Levels of $[Ca^{2+}]_i$ in quiescent isolated adult rat cardiomyocytes were measured as described previously (Xie *et al.*, 2003; Rah *et al.*, 2005). Briefly, cardiomyocytes attached to laminine-coated plates were loaded with 5 μ M Fluo 3-AM (Molecular Probe, Eugene, OR) in KH buffer containing 1% BSA at 37°C for 30 min, and the plates were washed three times with KH buffer and used for the treatment with various drugs. SR Ca^{2+} channel blockers, ryanodine (20 μ M) (Xie *et al.*, 2005) and dantrolene (2 μ M) (Buyukokuroglu *et al.*, 2004) and antioxidants, α -lipoic acid (100 μ M) (Cao *et al.*, 2003) and α -tocopherol (100 μ M) (Ulker *et al.*, 2003) were preincubated at 37°C for 20 min prior to treatment with DOX (3 μ M). Signal of $[Ca^{2+}]_i$ in cardiomyocytes was measured every 6 s for 90 min on confocal microscope (Nikon) equipped with air-cooled argon laser system. The emitted fluorescence at 530 nm was collected using photomultiplier tube, and $[Ca^{2+}]_i$ was estimated according to the following equation after subtracting the background DOX fluorescence: $[Ca^{2+}]_i = (K_d \cdot R) / [(K_d / [Ca^{2+}]_0) - R + 1]$, where R is the normalized fluorescence (F/F_0) and K_d is the dissociation constant of the Ca^{2+} -Fluo-3 complex (560 nM), and F is the observed fluorescence levels (Loughrey *et al.*, 2003). Each tracing was calibrated for the maximal intensity (F_{max}) by addition of ionomycin (8 μ M) and for the minimal intensity (F_{min}) by addition of EGTA (50 mM final) at the end of each measurement. During experiments, the temperature of dishes was maintained at 37°C using a microwarm plate.

Determination of ROS generation

Measurement of hydrogen peroxide formation was

performed using a fluorescent probe in isolated adult rat cardiomyocyte as previously described (Cominacini *et al.*, 2000). Briefly, cardiomyocytes attached to laminine-coated plates were loaded with 0.2 μ M (final concentration) of the peroxide-sensitive fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA, Molecular Probe, Eugene, OR) in HEPES buffer (pH, 7.4) containing 20 mM HEPES, 137 mM NaCl, 4.9 mM KCl, 1.2 mM $MgSO_4$, 15 mM glucose, and 10 mM BDM at 37°C for 30 min, and the plates were washed two times with HEPES buffer and used for the treatment with various drugs. RyR blockers, ryanodine (20 μ M) and dantrolene (2 μ M) and antioxidants, α -lipoic acid (100 μ M) and α -tocopherol (100 μ M) were preincubated at 37°C for 20 min prior to treatment with DOX (3 μ M). Fluorescence of ROS in cardiomyocytes was measured every 5 min for 90 min using a fluorescence photometer, Spectra Max Gemini (Molecular Devices, Sunnyvale, CA).

Measurement of caspase-3 activity

The enzyme activity was measured using fluorogenic substrate, N-acetyl Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) using a method provided by the manufacturer (BD Biosciences). Cardiomyocytes were attached to laminine-coated plates at 37°C for 10 min. After removing unattached cells, the cells were further incubated at 37°C for 2 h in M199 medium (Gibco, Invitrogen, Grand Island, NY) supplemented with 2 mg/ml BSA, 2 mM L-carnitine, 5 mM creatine, 5 mM taurine, 2 mM pyruvate, 100 IU/ml penicillin, and 100 μ g/ml streptomycin. For the experiments, the cells were pretreated with various drugs (20 μ M ryanodine, 50 μ M dantrolene, 100 μ M α -lipoic acid, or 100 μ M α -tocopherol) at 37°C for 20 min prior to addition of DOX (3 μ M). When α -lipoic acid was treated with ryanodine, α -lipoic acid was first treated for 20 min, and then the blocker was added and incubated for 20 min before addition of DOX. At the indicated time point, the cells were washed with ice-cold PBS (140 mM NaCl, 2.7 mM KCl, and 10 mM KH_2PO_4/K_2HPO_4 , pH 7.5). Excess of PBS was removed by aspiration, and the cells were immediately frozen at -80°C after addition of 500 μ l of a lysis buffer (10 mM Tris-HCl, 10 mM KH_2PO_4/K_2HPO_4 , pH 7.5, 130 mM NaCl, 1% Triton X-100, and 10 mM sodium pyrophosphate). The cells were harvested, homogenized, and centrifuged at 15,000 rpm at 4°C for 30 min. Supernatants were collected, and protein concentrations were determined as described above. Samples (100 μ g protein) were incubated with the substrate (20 μ M, final) at 37°C for 1 h. Fluorescence of 7-amino-4-methylcoumarin liberated from the fluorogenic substrate was determined at 380 nm excitation and 460 nm emission using a fluorescence photometer,




Figure 1. DOX induces Ca^{2+} release from intracellular stores. (A) Determination of $[Ca^{2+}]_i$ in the presence of extracellular Ca^{2+} (1 mM). (B) The Ca^{2+} signal in the absence of extracellular Ca^{2+} (Ca^{2+} free) was determined using KH buffer, which was prepared without addition of $CaCl_2$. Concentration of DOX was 3 μ M. (C) DOX does not activate L-type Ca^{2+} channel. L-type Ca^{2+} channel activation by DOX was determined in the presence of extracellular Ca^{2+} (1 mM) using a channel blocker, nifedipine (20 μ M). An arrow indicates the time point at where DOX was added. (D) Changes of $[Ca^{2+}]_i$ are presented mean \pm SEM. Nif indicates nifedipine. Cell numbers are presented in the parentheses. *, $P < 0.001$ versus basal $[Ca^{2+}]_i$.

Spectra Max Gemini (Molecular Devices, Sunnyvale, CA).

Statistical analysis

Data are expressed as mean \pm SEM. Statistical comparisons were performed using one-way ANOVA. Significant differences between groups were determined using the unpaired Student's *t* test. Statistical significance was set at $P < 0.05$.

Results

DOX induces Ca^{2+} release from intracellular Ca^{2+} stores in rat cardiomyocytes

Firstly, to elucidate the source of DOX-mediated increase of $[Ca^{2+}]_i$ in cardiomyocytes, Ca^{2+} signal was determined in the presence and absence of extracellular Ca^{2+} . Treatment of cardiomyocytes with DOX increased levels of $[Ca^{2+}]_i$ in the presence and absence of extracellular Ca^{2+} (Figure 1A and B). The

DOX-induced Ca^{2+} increase was very slow, beginning to increase at approximately 30 min after DOX treatment, reached plateau at approximately 70 min, and sustained. The time to start Ca^{2+} rise was somewhat DOX concentration-dependent. The Ca^{2+} release begun to increase at approximately 60 min and 15 min after treatment with 1 μ M and 5 μ M DOX, respectively. In addition, DOX has been shown to activate L-type channel (Keung *et al.*, 1991). Therefore, effect of a L-type Ca^{2+} channel blocker, nifedipine, on DOX-induced Ca^{2+} signal was examined. This blocker showed no effect on DOX-induced increase of $[Ca^{2+}]_i$ (Figure 1C). The Ca^{2+} levels at 75 min after DOX treatment are summarized in Figure 1D. These results suggest that DOX induces release of Ca^{2+} from intracellular stores in rat cardiomyocytes.

DOX induces Ca^{2+} release from isolated SR

A previous study has reported that DOX binds directly to RyR, thereby increases open probability (Saeki *et al.*, 2002) and that DOX-induced Ca^{2+} increase shows a similar pattern of RyR-mediated




Figure 2. DOX induces Ca²⁺ release from SR via RyR. (A) DOX increases binding of ryanodine by SR. The binding of [³H]ryanodine by SR was determined as detailed in Materials and Methods. The error bar shows SEM from three independent experiments in duplicate. *, $P < 0.05$ and **, $P < 0.001$ versus control. (B) Trace of Ca²⁺ uptake and DOX-induced increase of Ca²⁺ level in the reaction solution. Loading of Ca²⁺ (40 μM) was repeated 6 times. Ca²⁺ was added when the peak of Ca²⁺ fluorescence was reduced as indicated with an arrowhead. An arrow indicates the time point of DOX (3 μM) addition. The experiment was performed three times with similar results. (C) Time-dependent release of Ca²⁺ from SR. Ca²⁺ was loaded into SR as described in Materials and Methods. The Ca²⁺ release was monitored at indicated time after addition of DOX (3 μM). The error bar is SEM from three independent experiments. (D) DOX-induced Ca²⁺ release is blocked by pre-treatment with ryanodine (Ry) or α-lipoic acid (LA). The Ca²⁺-loaded SR preparation (70 μg) was preincubated with 20 μM ryanodine (Ry) or 100 μM α-lipoic acid at 37°C for 15 min. The Ca²⁺ level in the reaction buffer was determined at 30 min after treatment of Ca²⁺-loaded SR with DOX. The error bar shows SEM from three independent experiments in duplicate. * $P < 0.001$ versus control; # $P < 0.04$ versus DOX; ## $P < 0.001$ versus DOX.

Ca²⁺ signal (Kim *et al.*, 1989). The above data also suggest that DOX induces Ca²⁺ release from SR. An involvement of RyR in Ca²⁺ release was examined using SR preparations from rat hearts. The SR preparations showed high ryanodine binding activity (750 ± 5 nmole/mg), demonstrating that the preparation is SR-rich vesicles. Binding of [³H]ryanodine by the SR vesicles was modestly increased in a DOX dose-dependent manner (Figure 2A), and maximum increase (28 ± 5%) of ryanodine binding was observed at 6 μM DOX. Uptake of Ca²⁺ by SR

vesicles was observed, and treatment of these Ca²⁺-loaded vesicles with DOX resulted in an increase of Ca²⁺ level in the reaction solution (Figure 2B). The Ca²⁺ release was gradually increased in a time-dependent manner, reached plateau at approximately 20 min after DOX treatment, and then sustained (Figure 2C). Interestingly, the DOX-induced Ca²⁺ release was substantially inhibited by pretreatment with high concentration of ryanodine (20 μM, this concentration of ryanodine blocks RyR) (Figure 2D). Treatment of α-lipoic acid, which is a multi-

functional antioxidant, reduced approximately 20% DOX-induced Ca^{2+} release (Figure 2D). Together, these results suggest that DOX induces Ca^{2+} release from SR mainly through RyR.

DOX-induced Ca^{2+} increase is inhibited by Ca^{2+} channel blockers and antioxidants in rat cardiomyocytes

The above observations that DOX stimulates Ca^{2+}




Figure 3. DOX-mediated increase of $[Ca^{2+}]_i$ is inhibited by the RyR blockers or antioxidants. Prior to addition of DOX (3 μ M), cardiomyocytes were preincubated with and without ryanodine (Ry), dantrolene (Dan), α -lipoic acid (LA), or α -tocopherol (Toco) as described in Materials and Methods. (A) Inhibition of DOX-induced increase of $[Ca^{2+}]_i$. DOX-mediated increase of $[Ca^{2+}]_i$ is blocked by ryanodine (B), dantrolene (C), α -lipoic acid (D), or α -tocopherol (E). (F) A direct comparison of mean $[Ca^{2+}]_i$ at 75 min after treatment of DOX. The data are presented as mean \pm SEM. Cell numbers are indicated in the parentheses. * $P < 0.001$ versus basal $[Ca^{2+}]_i$; # $P < 0.001$ versus DOX-induced $[Ca^{2+}]_i$. An arrow indicates the time point of DOX addition.

release from SR via RyR were further evaluated using freshly isolated adult rat cardiomyocytes. Drugs with clearly defined effects on Ca²⁺ handling or ROS scavenging were used to explore DOX-mediated SR Ca²⁺ release. Pretreatment of a RyR blocker, ryanodine or dantrolene, inhibited DOX-induced Ca²⁺ rise (Figure 3B and C). Treatment of an antioxidant, α -lipoic acid or α -tocopherol, also blocked DOX-induced increase of [Ca²⁺]_i (Figure 3D and E). Blocking ability of SR Ca²⁺ channel blockers or antioxidants in DOX-induced Ca²⁺ rise observed at 75 min is summarized in Figure 3F. These data indicate that DOX-mediated increase in [Ca²⁺]_i is mainly due to opening of RyR and that there is a close link between Ca²⁺ release and ROS generation.

DOX-induced ROS generation is inhibited by the treatment of cardiomyocytes with antioxidants and Ca²⁺ channel blockers

To clarify a link between ROS generation and Ca²⁺ release induced by DOX, ROS production was determined as a function of time. Firstly, permeability of DOX was examined by determining intrinsic DOX fluorescence in cardiomyocytes. Presence of DOX in cardiomyocytes was found within 10 min and accumulated in the nucleus with time (Figure 4A). Similarly, the level of ROS was gradually increased in a time-dependent manner by the treatment of DOX (Figure 4B). The increase in ROS production was significantly reduced by the pretreatment with Ca²⁺ channel blockers, ryanodine and dantrolene (Figure 4C) or antioxidants, α -lipoic acid and α -tocopherol

(Figure 4D). A direct comparison of ROS levels are summarized in Figure 4E. These results suggest that DOX-induced ROS generation is a gradual process involving Ca²⁺.

Caspase-3 activation by DOX is inhibited by RyR blocker and antioxidant

Studies have shown that treatment of DOX results in activation of apoptotic pathways in which caspase-3 is activated (Yamaoka *et al.*, 2000; Kalivendi *et al.*, 2001; 2005; Jang *et al.*, 2004). To examine the effect of Ca²⁺ rise and ROS generation induced by DOX on cardiomyocytes, caspase-3 activity was determined. Treatment of cardiomyocytes with DOX increased caspase-3 activity in a time-dependent manner, reaching maximum at approximately 7 h after DOX treatment (Figure 5A). The DOX-induced caspase-3 activation was significantly inhibited by the pretreatment with ryanodine or dantrolene (Figure 5B). Ryanodine or dantrolene alone had no effects on caspase-3 activity. α -Lipoic acid also reduced the DOX-induced caspase-3 activation whereas α -tocopherol did not. Failure of α -tocopherol to block DOX-mediated activation of caspase-3 is probably due to loss of antioxidant capacity during long-term incubation. Cotreatment of ryanodine with α -lipoic acid completely inhibited caspase-3 activity (Figure 5B).

Discussion

In this study, the molecular basis of DOX-induced intracellular Ca²⁺ regulation has been examined




Figure 4. DOX-mediated ROS generation is inhibited by RyR blockers and antioxidants. (A) Permeability of DOX into rat cardiomyocytes. Cells were treated with 3 μ M DOX, washed with PBS, and then intrinsic DOX fluorescence was observed under a fluorescent microscope. Bar indicates 10 μ m.




Figure 4. (B) Treatment of DOX increases ROS production. As an assessment of ROS generation by DOX, H_2O_2 levels were determined with the fluorescent probe H_2DCFDA as detailed in Materials and methods. (C) DOX-induced ROS generation is inhibited by ryanodine (Ry) or Dantrolene (Dan). Cells were pretreated with ryanodine or dantrolene at $37^\circ C$ for 30 min. (D) DOX-induced ROS generation is inhibited by the treatment of α -lipoic acid (LA) and α -tocopherol (Toco). Prior to addition of DOX, cells were pretreated with α -lipoic acid or α -tocopherol as detailed in Materials and Methods. (E) A direct comparison of the ROS levels. Data are presented as mean \pm SEM from three independent experiments. * $P < 0.001$ versus; # $P < 0.005$ versus DOX.

utilizing adult rat cardiomyocytes. The results have revealed that DOX increases $[Ca^{2+}]_i$ by releasing Ca^{2+} from SR through RyR and that there is a close link between DOX-induced ROS generation and an increase of $[Ca^{2+}]_i$. Evidence for a link between ROS generation and Ca^{2+} increase is that 1) DOX-induced increase of $[Ca^{2+}]_i$ is inhibited by pretreatment of antioxidants and 2) ROS generation is blocked by pretreatment with the RyR blockers. These findings suggest that the amount of ROS generated by DOX is an amalgamation of DOX plus Ca^{2+} -induced ROS production.

To date, the Ca^{2+} channel(s) opened by DOX remains unclear. Studies have reported that DOX activates L-type channel (Keung *et al.*, 1991), inhibits Na^+ - Ca^{2+}

exchanger (Caroni *et al.*, 1981), or releases Ca^{2+} from SR (Zorzato *et al.*, 1985; Kim *et al.*, 1989). Our results have shown that DOX-mediated increase of $[Ca^{2+}]_i$ is due to a release of Ca^{2+} from SR through ROS-mediated opening of RyR. The DOX-mediated Ca^{2+} signal was increased in the presence of a L-type channel blocker, nifedipine or absence of extracellular Ca^{2+} . The DOX-mediated Ca^{2+} release was blocked by pretreatment with an antioxidants, α -lipoic acid or α -tocopherol, indicating that ROS causes opening of the receptor. Although the causative mechanism of ROS-mediated RyR opening is not clearly understood, the receptor is known to be sensitive to oxidation due to presence of a large number of thiols (Favero *et al.*, 1995). In addition, quinone-containing




Figure 5. Treatment of cardiomyocytes with DOX stimulates caspase-3 activity. (A) Caspase-3 activity was increased in a time-dependent manner by treatment of DOX (3 μ M). The caspase-3 activity was determined as detailed in Materials and methods. (B) DOX-stimulated caspase-3 activity is inhibited by treatment with RyR inhibitor or antioxidant. Cardiomyocytes were preincubated with 20 μ M ryanodine (Ry), 2 μ M dantrolene (Dan), 100 μ M α -lipoic acid (LA), 100 μ M α -tocopherol (Toco) or 20 μ M ryanodine plus 100 μ M α -lipoic acid at 37°C for 30 min. The data are presented mean \pm SEM from three independent experiments in duplicate. * P < 0.01 and ** P < 0.001 versus basal control (no drug treatment); # P < 0.01 and ## P < 0.001 versus DOX.

compounds such as DOX, 1,4-benzoquinone, and 1,4-naphthoquinone are shown to open RyR by oxidizing essential thiols in RyR (Feng *et al.*, 1999). Direct binding of DOX to RyR has also been reported (Saeki *et al.*, 2002). Similarly, with the isolated SR preparation, DOX increased ryanodine binding to the receptor in a dose-dependent manner, indicating an increase of high affinity state of RyR for ryanodine. However, with cardiomyocytes, there was no indication that binding of DOX to the receptor opens RyR, since treatment of antioxidants blocked almost completely the Ca²⁺ rise mediated by DOX. One of interesting findings is that although RyR is most likely opened by ROS, the RyR blockers are able to inhibit the Ca²⁺ release, resulting in attenuation of ROS generation.

A large number of studies has suggested a close relationship between enhancement of [Ca²⁺]_i and ROS generation (Brookes *et al.*, 2004). However, a link between DOX-mediated Ca²⁺ increase and ROS generation has not been studied. Our results indicate that DOX/ROS-mediated Ca²⁺ increase also generates ROS: DOX-induced ROS increase was inhibited by the treatment with high concentration of ryanodine or dantrolene. Consistent with the observations, studies have demonstrated that DOX-mediated ROS production is reduced by the treatment of endothelial cells and H9c2 cells with an intracellular Ca²⁺ chelator BAPTA (Kalivendi *et al.*, 2001; 2005). The increase of ROS generation is also observed in

cardiomyocytes or spleen cells by treatment with Ca²⁺ ionophore A23187 (Przygodzki *et al.*, 2005) or thapsigargin (Yip *et al.*, 2005), respectively. In addition, antioxidant properties of Ca²⁺ channel blockers have been observed with *in vivo* and *in vitro* studies (Buyukokuroglu *et al.*, 2001; 2004; Umamoto *et al.*, 2004; Ysunari *et al.*, 2005). The molecular mechanism by which the increased Ca²⁺ level promotes ROS production is not clearly understood. It has been shown that accumulation of Ca²⁺ in mitochondria promotes the generation of ROS (Brookes *et al.*, 2004). DOX-mediated enhancement of Ca²⁺-sensitive nitric oxide synthase expression leads to generation of ROS in endothelial cells (Kalivendi *et al.*, 2001). Recently, it has been demonstrated that dual oxidase-2, which belongs to NAD(P)H oxidase family, has an intrinsic Ca²⁺-dependent H₂O₂ generating activity (Ameziane-El-Hassani *et al.*, 2005). A similar Ca²⁺-sensitive ROS generating enzyme(s) may exist in rat cardiomyocytes.

In this study, as an assessment of cellular effect of DOX-induced Ca²⁺ rise and ROS generation on cardiomyocytes, caspase-3 activity has been examined. The data indicate that DOX/ROS-mediated increase of [Ca²⁺]_i plays a critical role in cardiomyocyte apoptosis. DOX-stimulated caspase-3 activity was significantly blocked by ryanodine and dantrolene. Interestingly, antioxidants used in this study showed different effects on the modulation of Ca²⁺ signal and

apoptosis. α -Lipoic acid and α -tocopherol inhibited DOX-induced increase in $[Ca^{2+}]_i$. However, DOX-mediated activation of caspase-3 was reduced by α -lipoic acid, but not by α -tocopherol. Although reason for these different effects of the antioxidants is not clearly understood, it may be due to different reducing capacity of the antioxidants. α -Lipoic acid and its reduced form, dihydrolipoic acid (DHLA), have been referred to as "a universal antioxidant" that functions in both membrane and aqueous phases (Packer *et al.*, 1995). Both α -lipoic acid and DHLA have substantial antioxidant properties. These include their ability to directly quench a variety of reactive oxygen species, inhibit reactive oxygen-generators, and spare other antioxidants. α -Tocopherol, including other vitamins (vitamin A and C) has been shown to exhibit limited reducing power in inhibiting DOX-induced cardiomyopathy and apoptosis (Ulker *et al.*, 2003; Minotti *et al.*, 2004). In addition, we have also found that cotreatment of ryanodine and α -lipoic acid further attenuates DOX-stimulated caspase-3 activation blocked by treatment of individual agent, indicating that the activation of caspase-3 by DOX is largely due to ROS and Ca^{2+} .

Cardiomyopathy induced by DOX therapy is a continuing clinical problem. Our results demonstrate that DOX/ROS stimulates opening of RyR, resulting in a rise of $[Ca^{2+}]_i$. The data have also suggested that ROS produced by DOX is an amalgamation of ROS generated by both DOX and the increased Ca^{2+} and that the DOX/ROS-mediated Ca^{2+} increase plays a key role in DOX-mediated caspase-3 activation. These findings also provide a molecular basis of alteration of Ca^{2+} homeostasis by DOX.

Acknowledgement

We thank Ruksana Gul for the preparation of cardiomyocytes. This work is supported by the Korea Research Foundation Grant E00002 (to Uh-Hyun Kim).

References

- Ameziane-El-Hassani R, Morand S, Boucher JL, Frapart YM, Apostolou D, Agnandji D, Gnidehou S, Ohayou R, Noel-Hudson MS, Francon J, Lalaoui K, Virion A, Dupuy C. Dual oxidase-2 has an intrinsic Ca^{2+} -dependent H_2O_2 -generating activity. *J Biol Chem* 2005;280:30046-54
- Brookes PS, Yoon Y, Robothan JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *Am J Physiol Cell Physiol* 2004;287:C817-33
- Buyukokuroglu ME, Gulcin I, Oktay M, Kufrevioglu OI. *In vitro* antioxidant properties of dantrolene sodium. *Pharmacol Res* 2001;44:491-4
- Buyukokuroglu ME, Taysi S, Buyukavci M, Bakan E. Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. *Hum Exp Toxicol* 2004;23:251-6
- Cao Z, Tsang M, Zhao H, Li Y. Induction of endogenous antioxidants and phase 2 enzymes by α -lipoic acid in rat cardiac H9c2 cells: protection against oxidative injury. *Biochem Biophys Res Comm* 2003;310:979-85
- Caroni P, Villani F, Carafoli E. The cardiotoxic antibiotic doxorubicin inhibits the Na^+/Ca^{2+} exchange of dog heart sarcolemmal vesicles. *FEBS Lett* 1981;30:184-6
- Chamberlain BK, Fleisher S. Isolation of canine cardiac sarcoplasmic reticulum. *Methods Enzymol* 1988;57:91-9
- Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment *in vivo* causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity and Bcl-2:Bax ratio. *Cancer Res* 2002;62:4592-8
- Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Cascio VL, Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF- κ B through an increased production of intracellular reactive oxygen species. *J Biol Chem* 2000;275:12633-8
- Doroshov JH, Davies KJ. Redox cycling of anthracycline by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem* 1986;261:3068-74
- Favero TG, Zable AC, Abramson JJ. Hydrogen peroxide stimulates the Ca^{2+} release channel from skeletal muscle sarcoplasmic reticulum. *J Biol Chem* 1995;270:25557-63
- Feng W, Liu G, Xia R, Abramson JJ, Pessah IN. Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinines. *Mol Pharmacol* 1999;55:821-31
- Gutierrez PL. The role of NAD(P)H oxidoreductase (DT-diphosphorase) in the bioactivation of quinone-containing antitumor agents. *Free Radic Biol Med* 2000;29:263-75
- Jang YM, Kendaiah S, Drew B, Philips T, Selman C, Julian D, Leeuwenburgh C. Doxorubicin treatment *in vivo* activates caspase-12 mediated cardiac apoptosis in both male and female rats. *FEBS Lett* 2004;577:483-90
- Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Klayanataman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. *J Biol Chem* 2001;276:47266-76
- Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, Klayanataman B. Doxorubicin activity nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. *Biochem J* 2005;389:527-39
- Keung EC, Toll L, Ellis M, Jensen RA. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats: morphological, biochemical, and functional correlations. *J Clin Invest* 1991;87:2108-13
- Kim DH, Landry AB, Lee YS, Katz AM. Doxorubicin-induced calcium release from sarcoplasmic reticulum vesicles. *J Mol*

Cell Cardiol 1989;21:433-6

Loughrey CM, MacEachern KE, Cooper J, Smith GL. Measurement of the dissociation constant of Fluo-3 for Ca²⁺ in isolated rabbit cardiomyocytes using wave characteristics. Cell Calcium 2003;34:1-9

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229

Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ, Cusack BJ. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 2000;109:168-76

Packer L, Wifl EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol Med 1995;19:227-50

Petrosillo G, Ruggiero F, Pistolesse M, Paradies G. Ca²⁺-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms. J Biol Chem 2004;279:53103-8

Przygodzki T, Sokal A, Bryszewska M. Calcium ionophore A 23187 action on cardiomyocytes is accompanied by enhanced production of reactive oxygen species. Biochim Biophys Acta 2005;1740:481-8

Rah SY, Park KH, Han MK, Im MJ, Kim UH. Activation of CD38 by interleukine-8 signaling regulates intracellular Ca²⁺ level and motility of lymphokine-activated killer cells. J Biol Chem 2005;280:2888-95

Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Mtsunoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 2002;70:2377-89

Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS, Olson RD. Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 2000;60:1435-44

Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5

Takeda S, Prejapati D, Mochizuki S, Elimban V, Dhalla NS. Attenuation of ischemia-reperfusion induced changes in cardiac performance and sarcoplasmic reticulum function by vanadate. Exp Cardiol 2003;8:134-8

Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse Endothelial Dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension 2003;41:534-9

Umamoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004;27:877-85

Waring P. Redox active calcium ion channels, cell death. Arch Biochem Biophys 2005;434:33-42

Xie GH, Rah SY, Yi KS, Han MK, Chae SW, Im MJ, Kim UH. Increase of intracellular Ca²⁺ during ischemia/reperfusion injury of heart is mediated by cyclic ADP-ribose. Biochem Biophys Res Commun 2003;307:713-8

Xie GH, Rah SY, Kim SJ, Nam TS, Ha KC, Chae SW, Im MJ, Kim UH. ADP-ribosyl cyclase couples to cAMP signaling in the cardiomyocytes. Biochem Biophys Res Commun 2005;330:1290-8

Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y, Tomoike H. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 2000;32:881-9

Yip KH, Zheng MH, Steer JH, Giardina TM, Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA, Xu J. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. J Bone Miner Res 2005;20:1462-71

Ysunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J. Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res 2005;26:107-12

Zorzato F, Sarvati G, Facchinetti T, Volpe P. Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. J Cell Biol 1985;99:875-85